Traffic Lights - Latest Updates

Last updated: 05/09/2022

Other updates on this site
Drug Name Classification Clinical Indication Comments
BARICITINIB (NEW) Red For use in monogenic interferonopathies (adults and children 2 years and over)

Clinical Commissioning Policy

BUDESONIDE/ FORMOTEROL FUMARATE DIHYDRATE INHALER (GoResp Digihaler®) Do not prescribe

Discontinued June 2024 – see MHRA alert

CLONIDINE ORAL (NEW) Yellow For Tic Disorders including: Chronic Motor Tic Disorder, Chronic Vocal Tic Disorder, Transient Tic Disorder and Tourette Syndrome. Off-label indication
DAPAGLIFLOZIN / METFORMIN (Xigduo®) (UPDATED) Do not prescribe Type 2 diabetes

Not accepted locally for use. Use individual components.

DOXEPIN (NEW) Do not prescribe Depression

Not accepted locally for use in depressive illness.

Existing patients should be reviewed to an alternative.

ENOXAPARIN Green Thromboprophylaxis and treatment of DVT and PE

Prescribe by brand name INHIXA® as different brands have different injection techniques.

Courses started during the dalteparin shortage can be continued to be supplied in primary care

MULTIVITAMIN AND MINERAL SUPPLEMENT (Forceval) (NEW) Green

Restricted for for use in gastric bypass / BPD/DS bariatric surgery on the recommendation of a dietician

Restricted for for use in line with the out of hours enteral feeding tube guidelines only

Restricted for micronutrient supplementation for patients with intestinal failure

See Formulary

NEPAFENAC (Nevanac®) Red Pain and inflammation post cataract surgery and Cystoid Macular Oedema in Uveitic Patients
OCTEROTIDE (UPDATED) Yellow Vomiting in palliative care, initiation by specialist palliative care team only

See formulary

OCTEROTIDE (UPDATED) Red

Multiple indications see Formulary

PALOPEGTERIPARATIDE (Yorvipath) Grey

Review deferred pending NICE outcome.

RITLECITINIB (Litfulo) Red Severe alopecia areata in people 12 years and over

In line with NICE TA 958.

 

RITUXIMAB Red IgM paraproteinaemic demyelinating peripheral neuropathy in adults
SPF 50+ SUNSCREEN PREPARATIONS (Anthelios) (NEW) Green Borderline Substance: only for patients with photosensitive disorder with widespread dysplastic lesions and/or a history of skin cancer

Restricted Green. Patients should be encouraged to purchase sun screens OTC as per LLR Self-Care Guidelines

Tixagevimab plus Cilgavimab Do not prescribe

Not recommended, within its marketing authorisation, for treating COVID‑19 as per NICE TA971.

TOBRAMYCIN inhalation Red Cystic fibrosis

Available as nebuliser solution (Vantobra®, Bramitob®) and dry powder for inhalation (Tobi ® podhaler).

USTEKINUMAB Red For refractory Crohn’s disease in pre-pubescent children (aged < 6 years old)

In line with NHSE Clinical Commissioning Policy.

VADADUSTAT (Vafseo) (NEW) Red Aymptomatic anaemia in adults having dialysis for chronic kidney disease

Funding from 23/04/2025

NICE TA1035

VAMOROLONE (Agamree) (NEW) Red Duchenne muscular dystrophy in people 4 years and over

In line with NICE TA1031.

Other Updates on this Website

Recent documents from LLR APC and TAS


About the Leicester, Leicestershire and Rutland Area Prescribing Committee

In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more